"CZ - \u010Cesk\u00E1 republika" . "1213-8118" . "P(NS10286), S, Z(MSM6198959216)" . "BOUCHALOV\u00C1, Kate\u0159ina" . . . . . . . . . . . "CWIERTKA, Karel" . . "\u010C\u00CD\u017DKOV\u00C1, Magdalena" . "8"^^ . . . . . . "Hajd\u00FAch, Mari\u00E1n" . . "154" . . "15110" . "4" . "Biomedical Papers" . "LAPATINIB IN BREAST CANCER ? THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT."@en . . "FRIEDECK\u00DD, David" . "Breast cancer treatment trends are currently based on tailored therapies using tumor and patient biomarkers. Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1)and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice. However, only HER2 is currently used for therapy indications and new predictors for the treatment with lapatinib are sought."@en . . . "LAPATINIB IN BREAST CANCER ? THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT."@en . "LAPATINIB IN BREAST CANCER ? THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT." . . . "Breast cancer treatment trends are currently based on tailored therapies using tumor and patient biomarkers. Lapatinib is the first dual inhibitor of HER1 (EGFR, ErbB1)and HER2 (ErbB2, Neu) tyrosine kinases to be used in clinical practice. However, only HER2 is currently used for therapy indications and new predictors for the treatment with lapatinib are sought." . . . . . . "RIV/61989592:15110/10:10214978" . . . "[35635D93CA57]" . "6"^^ . "LAPATINIB IN BREAST CANCER ? THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT." . "RIV/61989592:15110/10:10214978!RIV11-MZ0-15110___" . "267891" . . "Lapatinib plasma level; Metastatic breast cancer; Biological therapy; Targeted therapy; Dual tyrosine kinase inhibitor; PIK3CA; PTEN; HER2 (ErbB2, Neu); HER1 (EGFR, ErbB1); Lapatinib"@en . "6"^^ . . "TROJANEC, Radek" .